Answers are grounded in this paper and cite their sources.
Commodification of low-cost diagnostic technologies (LCDTs) carries the risk of an unintended and potentially worrisome shift in how we conceive of health assessment. Optimizing practice requires a balanced understanding of both the beneficial and harmful impact of the use of LCDTs and the development of system incentives for appropriate use.
No takes yet. Share an insight, caveat, or question.
Lewis et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: